Trial reportBMC complementary and alternative medicine2018
Effects of green tea extract on overweight and obese women with high levels of low density-lipoprotein-cholesterol (LDL-C): a randomised, double-blind, and cross-over placebo-controlled clinical trial.
Trial report in BMC complementary and alternative medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02116517 (Phase 3 Study; Effects of Green Tea Extract on Obese Women With High Level of Low Density Lipoprotein), which is not on this map. Cited by 39 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Phase 3 Study; Effects of Green Tea Extract on Obese Women With High Level of Low Density Lipoprotein (LDL): a Randomized, Double-blinded, and Cross-over Placebo-controlled Clinical Trial
Who cites it
39 citing papers in PubMed, 2 syntheses or guidelines pooled it, 87 citations in OpenAlex.
- Effect of green tea consumption on blood lipids: a systematic review and meta-analysis of randomized controlled trials.Nutrition journal · 2020Pooled it
- The Pharmacological Activity ofBiomolecules · 2020Pooled it
- Antiobesity and Hypolipidemic Potential ofNutrients · 2024Trial
- The combined effect of green tea and α-glucosyl hesperidin in preventing obesity: a randomized placebo-controlled clinical trial.Scientific reports · 2021Trial
- Trial
- Hypocholesterolemic agents and the gut microbiota: a review of interactions and modulatory activity.Pharmacological reports : PR · 2026Review
- The Potential Role of Dietary (Poly)phenols in Cardiometabolic Risk During Menopause: A Narrative Review.Nutrients · 2026Review
- Herbal adjuvant therapy with a combination of Green Tea, Persian Borage, and Purslane to reduce antipsychotic-induced weight gain in Schizophrenia: A randomized controlled trial.Avicenna journal of phytomedicine · 2026Article
- Review
- The Effect of Green Tea Beverage on Blood Cardiometabolic Risk Biomarkers in Dyslipidemia Subjects.Food science & nutrition · 2025Article
- Cardioprotective and Anti-Hypertensive Effects of Epigallocatechin Gallate: Novel Insights Into Biological Evidence.Journal of clinical hypertension (Greenwich, Conn.) · 2025Review
- Associations between green tea drinking and body mass index, serum lipid profile and prostate-specific antigen in a Ghanaian population: a cross-sectional study.BMC nutrition · 2025Article
- Nanotechnology-driven EGCG: bridging antioxidant and therapeutic roles in metabolic and cancer pathways.Nanomedicine (London, England) · 2025Review
- The Safety and Efficacy of Dietary Epigallocatechin Gallate Supplementation for the Management of Obesity and Non-Alcoholic Fatty Liver Disease: Recent Updates.Biomedicines · 2025Review
- Molecular Mechanisms Underlying the Therapeutic Potential of Plant-Based α-Amylase Inhibitors for Hyperglycemic Control in Diabetes.Current diabetes reviews · 2025Review
- White Tea Consumption Alleviates Anthropometric and Metabolic Parameters in Obese Patients.Medicina (Kaunas, Lithuania) · 2024Article
- Probiotics, prebiotics, synbiotics and other microbiome-based innovative therapeutics to mitigate obesity and enhance longevity via the gut-brain axis.Microbiome research reports · 2024Review
- Impact of Green Tea Consumption on the Prevalence of Cardiovascular Outcomes: A Systematic Review.Cureus · 2023Review
- (-)-Epigallocatechin-3-Gallate Reduces Perfluorodecanoic Acid-Exacerbated Adiposity and Hepatic Lipid Accumulation in High-Fat Diet-Fed Male C57BL/6J Mice.Molecules (Basel, Switzerland) · 2023Article
- Effects of green tea catechin on the blood pressure and lipids in overweight and obese population-a meta-analysis.Heliyon · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundThis study aims to examine the effects of green tea extract (GTE) supplement on overweight and obese women with high levels of low density lipoprotein-cholesterol (LDL-C).
methodsThe randomized, double-blind, crossover and placebo-controlled clinical trial was conducted from August 2012 to December 2013. Seventy-three out of 90 subjects aged between 18 and 65 years, with body mass index (BMI) ≥ 27 kg/m
resultsSubjects treated with GTE (n = 73) for 6 weeks showed significant differences, with 4.8% (p = 0.048) reduction in LDL-C and 25.7% (p = 0.046) increase in leptin. However, there was no statistical difference in the levels of total cholesterol, triglyceride and high density lipoprotein between the GTE and placebo groups after treatments.
conclusionsThis study shows that green tea extract effectively increases leptin and reduces LDL in overweight and obese women after 6 weeks of treatment even though there were no significant changes in other biochemical markers related to overweight.
trial registrationThis clinical trial is registered with ClinicalTrials.gov: NCT02116517 on 17 April 2014. Retrospectively registered. The first patient enrolled in October 2012 and the study was completed December 2013.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.